<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618420</url>
  </required_header>
  <id_info>
    <org_study_id>17-0820</org_study_id>
    <nct_id>NCT03618420</nct_id>
  </id_info>
  <brief_title>Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function</brief_title>
  <acronym>CASPER</acronym>
  <official_title>CASPER Study: Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from
      cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality
      in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia
      and hypertension, are beneficial, but only partially protect against DKD.

      Hyperfiltration is common in youth with T1D, and predicts progressive DKD. Hyperfiltration is
      also associated with early changes in intrarenal hemodynamic function, including increased
      renal plasma flow (RPF) and glomerular pressure. Intrarenal hemodynamic function is strongly
      influenced by the renin-angiotensin-aldosterone system (RAAS), which is also considered a key
      player in the pathogenesis of DKD. Preliminary data demonstrate differences in intrarenal
      hemodynamic function and RAAS activation in early and advanced DKD in T1D. However, the
      pathophysiology contributing to the differences observed in RAAS activation and intrarenal
      hemodynamic function in T1D are poorly defined Animal research demonstrates that arginine
      vasopressin (AVP) acts directly to modify intrarenal hemodynamic function, but also
      indirectly by activating RAAS. Preliminary data suggest that elevated copeptin, a marker of
      AVP, which predicts DKD in T1D adults, independently of other risk factors. However, no human
      studies to date have examined how copeptin relates to intrarenal hemodynamic function in
      early DKD in T1D. A better understanding of this relationship is critical to inform
      development of new therapies targeting the AVP system in T1D. Accordingly, in this study, the
      investigators propose to define the relationship between copeptin and intrarenal hemodynamics
      in early stages of DKD, by studying copeptin levels, renal plasma flow, and glomerular
      filtration in youth (n=50) aged 12-21 y with T1D duration &lt; 10 y.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All study participants will receive the same intervention.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Copeptin levels</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by fasting blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by PAH clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by iohexol clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Perfusion</measure>
    <time_frame>10 min</time_frame>
    <description>Measured by Arterial Spin Labeling (ASL) MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Oxygenation</measure>
    <time_frame>60 min</time_frame>
    <description>Measured by Blood Oxygen Level Dependent (BOLD) MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Nephropathy</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Juvenile Diabetes</condition>
  <condition>Diabetes Mellitus Complication</condition>
  <condition>Autoimmune Diabetes</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminohippurate Sodium Inj 20%</intervention_name>
    <description>Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)</description>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <other_name>Aminohippuric acid</other_name>
    <other_name>Para-aminohippurate</other_name>
    <other_name>Sodium 4-amino hippurate (PAH) inj 20% 2g/10 mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol Inj 300 mg/mL</intervention_name>
    <description>Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <other_name>omnipaque 300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antibody+ T1D with &lt;10 yr duration

          -  Age 12-21 years

          -  BMI ≥ 5%ile

          -  Weight&lt;350 lbs and &gt; 57 lbs.

          -  No anemia

          -  HbA1c &lt;12%

        Exclusion Criteria:

          -  Severe illness, recent diabetic ketoacidosis (DKA)

          -  Estimated Glomerular Filtration Rate (eGFR) &lt;60ml/min/1.73m2 or creatinine &gt; 1.5mg/dl
             or history of ACR≥300mg/g

          -  Anemia or allergy to shellfish or iodine

          -  Pregnancy or nursing

          -  MRI scanning contraindications (claustrophobia, implantable devices, &gt;350 lbs)

          -  Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB),
             diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or
             aspirin, sulfonamides, procaine, thiazolsulfone or probenecid, atypical antipsychotics
             and steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petter Bjornstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Denver</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

